Abstract:Background: Most randomized controlled trials with a time-to-event outcome are designed assuming proportional hazards (PH) of the treatment effect. The sample size calculation is based on a logrank test. However, non-proportional hazards are increasingly common. At analysis, the estimated hazards ratio with a confidence interval is usually presented. The estimate is often obtained from a Cox PH model with treatment as a covariate. If non-proportional hazards are present, the logrank and equivalent Cox tests may lose power. To safeguard power, we previously suggested a 'joint test' combining the Cox test with a test of non-proportional hazards. Unfortunately, a larger sample size is needed to preserve power under PH. Here, we describe a novel test that unites the Cox test with a permutation test based on restricted mean survival time. Methods: We propose a combined hypothesis test based on a permutation test of the difference in restricted mean survival time across time. The test involves the minimum of the Cox and permutation test P-values. We approximate its null distribution and correct it for correlation between the two P-values. Using extensive simulations, we assess the type 1 error and power of the combined test under several scenarios and compare with other tests. We investigate powering a trial using the combined test. Results: The type 1 error of the combined test is close to nominal. Power under proportional hazards is slightly lower than for the Cox test. Enhanced power is available when the treatment difference shows an 'early effect', an initial separation of survival curves which diminishes over time. The power is reduced under a 'late effect', when little or no difference in survival curves is seen for an initial period and then a late separation occurs. We propose a method of powering a trial using the combined test. The 'insurance premium' offered by the combined test to safeguard power under non-PH represents about a single-digit percentage increase in sample size. Conclusions: The combined test increases trial power under an early treatment effect and protects power under other scenarios. Use of restricted mean survival time facilitates testing and displaying a generalized treatment effect.

Stratified modestly-weighted log-rank tests in settings with an anticipated delayed separation of survival curves

Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance

Quantifying treatment differences in confirmatory trials under non-proportional hazards

The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities

A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching

Optimality of testing procedures for survival data

Consideration of stratification in confirmatory trials with time-to-event endpoint

A Class of Weighted Log-Rank Tests for Survival Data when the Event is Rare

Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials

Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated

Adaptive Promising Zone Design for Cancer Immunotherapy with Heterogeneous Delayed Treatment Effect

A Simulation-free Group Sequential Design with Max-combo Tests in the Presence of Non-proportional Hazards

Studentized Permutation Method for Comparing Restricted Mean Survival Times with Small Sample from Randomized Trials

Studentized Permutation Method for Comparing Two Restricted Mean Survival Times with Small Sample from Randomized Trials.

The weighted log-rank tests based on stratified clustered survival data: saddle-point p-values and confidence intervals

A two-step approach for analyzing time to event data under non-proportional hazards

A Novel Stratified Analysis Method for Testing and Estimating Overall Treatment Effects on Time-to-Event Outcomes Using Average Hazard with Survival Weight

Estimand-based Inference in Presence of Long-Term Survivors

A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome

More powerful logrank permutation tests for two-sample survival data